Current read
Proof of concept from 2 study records, 31 active source records, 11 rapid briefs, and 0 timeline events. Evidence maturity is 15/100, human translation signal is 62/100, and frontier activity is moderate (55/100). Frontier activity means research movement, not settled human proof.
This lane has plausible intervention signals but is not mature human evidence.
Commercial bias penalty: 77/100. Confidence: 44/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Chronic inflammatory tone, immunosenescence, autoimmunity signals, infection resilience, and safety tradeoffs. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 36/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
Inflammation-risk framing, immune-modulating biologics, infection and vaccine context.
What would move this row up?
Current bottleneck
evidence maturity
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Open evidence gaps
These gaps are matched from the evidence-gap ledger where possible, with row-level placeholders used when the graph is not yet enriched.
Human trials showing functional resilience or disease-risk changes from immune-aging interventions.
Human trials showing functional resilience or disease-risk changes from immune-aging interventions.
Validated inflammatory biomarkers tied to outcomes rather than vague inflammation language.
Validated inflammatory biomarkers tied to outcomes rather than vague inflammation language.
Evidence that would change the map
- Raise evidence maturity from 15/100 with better controlled studies or stronger replication.
- Raise human translation from 36/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not use inflammation as a universal villain word.
- Do not present immune modulation as simple immune boosting.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
No structured study records are attached to this row yet.
Useful source library entries
Related briefs
FDA Is Reviewing Compounded Peptide-Clinic Favorites
FDA's July advisory meeting covers BPC-157, Semax, Epitalon-related substances, MOTS-c, TB-500, KPV, DSIP/emideltide, and other peptide-related bulk substances popular in longevity circles.
Why now
The FDA calendar puts several longevity-clinic peptide favorites into a formal public regulatory review window.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Flagged a Serious Omnipod Insulin-Delivery Recall
Certain Omnipod Pods may leak insulin because of a cannula tear, creating under-delivery risk that can lead to hyperglycemia or diabetic ketoacidosis.
Why now
FDA's Class I classification makes this an urgent patient-safety story for insulin-dependent diabetes users who may have affected Pods.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
FDA Warns on Unapproved Cell and Tissue Products After Death Reports
FDA says unapproved human cell and tissue products marketed online may pose serious risks, including reports of patient deaths after use.
Why now
The gray-market regenerative medicine boom needs a clean evidence boundary alongside real cell and gene therapy breakthroughs.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 30, 2026
FDA Expands Tzield to Newly Diagnosed Children With Type 1 Diabetes
Tzield can now be used to delay insulin-production decline in certain children ages 8 to 17 recently diagnosed with stage 3 type 1 diabetes.
Why now
T1D is shifting from only insulin replacement to immune-timing and beta-cell preservation stories.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 30, 2026
GLP-1 Drugs Linked to Higher Smell and Taste Disturbance Risk
A large EHR cohort study found GLP-1 RA users with type 2 diabetes had higher documented smell and taste disturbance risk, though absolute rates were low.
Why now
GLP-1 safety signals are socially viral and need careful absolute-risk framing.
- Overclaim risk
- medium-high
- Primary source
- Primary
- Published
- Jun 30, 2026
FDA Panel Will Review Popular Longevity Peptides Amid Safety and Evidence Concerns
FDA advisers will review whether several popular peptides should be allowed for certain pharmacy compounding uses, while FDA materials flag limited human evidence and potential safety or quality concerns.
Why now
The peptide gray market just got a real FDA spotlight: BPC-157, TB-500, MOTS-c, Semax, and Epitalon are heading into a public review.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jun 30, 2026
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
Seed Oils: Toxic Sludge or Internet Scapegoat?
Seed oils are blamed for inflammation, obesity, heart disease, and metabolic collapse. The stronger signal is not that linoleic-acid-rich oils are toxic. It is that they often travel inside ultra-processed food patterns.
VV Signal Score
55
Early or context-dependent
- Sources
- 7
- Studies
- 6
- Claims
- 10
Sleep Is More Than Hours—and Less Certain Than the Headlines
Poor sleep tracks with inflammation, chronic disease, and mortality risk. The signal is meaningful, but the strongest outcome evidence is observational—not proof that a better sleep score adds years to life.
VV Signal Score
65
Promising signal
- Sources
- 6
- Studies
- 6
- Claims
- 6
Claim ledger
Related claims
Claim ledger records matched by topic, intervention, study, or source links.
sleep: Sleep disturbance has biologically plausible links to inflammatory and
Sleep disturbance has biologically plausible links to inflammatory and immune dysregulation through cytokine, neuroendocrine, autonomic, and antiviral-response pathways, but inflammation mediation between sleep and mortality is not settled.
seed oils: The blanket claim that seed oils cause inflammation is
The blanket claim that seed oils cause inflammation is not supported by human trial-review evidence on linoleic acid and inflammatory markers in healthy adults.
seed oils: Omega-6 fats are not inherently pro-inflammatory in the simple
Omega-6 fats are not inherently pro-inflammatory in the simple viral sense; mechanistic plausibility does not override human outcome and marker evidence.